Close
Help





JOURNAL

Clinical Medicine Insights: Therapeutics

Novel Agents and Emerging Treatment Strategies in Multiple Sclerosis. What Role for Cladribine?

Submit a Paper


Clinical Medicine Insights: Therapeutics 2011:3 425-439

Review

Published on 06 Oct 2011

DOI: 10.4137/CMT.S6456


Further metadata provided in PDF



Sign up for Email Alerts and keep in touch with Clinical Medicine Insights: Therapeutics journal news, updates, events and articles

Abstract

Multiple sclerosis (MS), a chronic inflammatory-degenerative illness of the central nervous system (CNS), remains at the moment a treatable but incurable disease. Currently available disease-modifying agents (DMA-s), the majority of which are being injected, mainly relieve the inflammatory phase of MS with little beneficial effect, if any, in halting neurodegeneration. Cladribine is an immunosuppressive agent that can be administered orally and by cycles of short-course dosing as opposed to continuous administration. Cladribine has been shown to be effective in reducing inflammatory activity of MS but much remains unknown regarding its potential beyond the control of CNS inflammation. In addition, knowledge on the safety profile of cladribine in MS is limited. Data from on going clinical studies and registries on its safety profile will shed more light on the actual benefit/risk ratio of cladribine.



Downloads

PDF  (649.76 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)




What Your Colleagues Say About Clinical Medicine Insights: Therapeutics
testimonial_image
I was delighted to submit an invited review on cluster headache pharmacology.  As someone who writes a few papers per year on these subjects, I appreciated that the submission, review and approval process for the paper was smooth and efficient. Our reviewers raised important points that improved the overall quality of the manuscript. Overall a very positive experience.
Dr Michael J. Marmura (Thomas Jefferson University, Philadelphia, PA, USA)
More Testimonials

Quick Links


New article and journal news notification services